Analysis of Blood Metabolomics to Identify Potential Biomarkers of Gastrointestinal Bleeding

Analysis of Metabolomics of Blood Degradation/Digestion Using in Vitro Digestion Model to Identify Potential Biomarkers of Gastrointestinal Bleeding

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05547360

Enrollment

Registered

2022-09-21

Start date

2022-07-19

Completion date

2022-12-31

Last updated

2022-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GastroIntestinal Bleeding

Keywords

in vitro digestion, Metabolomics, gastrointestinal tract

Brief summary

Despite advances in gastrointestinal endoscopy and pharmaceuticals, gastrointestinal bleeding is still a significant emergency disease with a high mortality rate of 1.9-5 per 100 people due to excessive bleeding and shock. There are several indicators using pulse rate, blood pressure, hemoglobin, etc. to select patients who require endoscopic intervention, or hospitalization, but these are inaccurate and with a high false-positive rate and low specificity at 35-40%. Therefore, tests with high diagnostic accuracy for gastrointestinal bleeding patients are required and findings specific biomarkers for gastrointestinal bleeding are of great importance.

Detailed description

Recently, with the development of metabolomics, efforts are being made to improve the diagnosis and treatment of diseases through metabolomics analysis, but there are no studies related to gastrointestinal bleeding. If the degradation/metabolism process of blood that accumulates in the gastrointestinal tract is well studied and understood, there is a possibility of finding specific biomarkers for gastrointestinal bleeding. Thus, this study aims to analysis of metabolomics of blood degradation/digestion using in vitro digestion model to identify potential biomarkers of gastrointestinal bleeding.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

21 Years to 55 Years

Inclusion criteria

1. Male and female participants, aged between 21 and 55 years old. 2. A body mass index (BMI) between 18.5 and 29.9 kilograms per meter square. 3. English-literate and able to give informed consent in English.

Exclusion criteria

1. Smokers. 2. Clinically significant allergic, renal, cardiac, bronchopulmonary, vascular, gastrointestinal, neurological, metabolic or immunodeficiency disorders, cancer, hepatitis, or cirrhosis. 3. Had surgery of the gastrointestinal tract or any other medical condition considered likely to affect the gastrointestinal absorption. 4. Use of oral iron supplement within the past 30 days. 5. Consumes more than 2 alcoholic drinks per day i.e. one drink is defined as either 150ml of wine, 340ml of beer/cider or 45ml of distilled spirit. 6. Significant change in weight (≥ 3 kg body weight) in the past 3 months. 7. Significant exercise pattern over the past 3 months defined as high-intensity exercise of more than 3 hours per week. 8. Poor peripheral venous access based on past experiences with blood draw

Design outcomes

Primary

Measure	Time frame	Description
blood metabolites	through study completion, an average of 5 months	screening of blood metabolites in digested blood (qualitative measure, untargeted analysis, using LC-qtof-MS and GC-MS)

Countries

Singapore

Contacts

Primary ContactJung Eun Kim, Ph.D

fstkje@nus.edu.sg6516 1136

Backup ContactYuanhang Yao

yuanhang@u.nus.edu8308 1987

Outcome results